My greatest concern is that the Board will fumble the distinction between pain relief and DMOAD and finish up with a longer path to significant revenue (an MPS deal excluded).
They need to separate the two in discussions with the FDA; so that an early pain and relief option is available. Otherwise the FDA may steer them to the all-encompassing labeling. We know from experience that the FDA likes to add little bits of work and we know that cycle added 9 months.
Ann: Investor Presentation - $66m Capital Raise, page-63
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 33599 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 65498 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |